Stroke RSS Page 5

Filtered By:
Condition: Atrial Fibrillation
Countries: UK Health

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 94 results found since Jan 2013.

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research

Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches
CONCLUSIONS: Screening for NVAF at ≥75 years of age could result in fewer NVAF-related strokes. NVAF screening is cost-effective and may be cost-saving depending on the program chosen.PMID:36757910 | DOI:10.1080/13696998.2023.2179210
Source: Journal of Medical Economics - February 9, 2023 Category: Health Management Authors: Shreeya Patel Thitima Kongnakorn Andreas Nikolaou Yassir Javaid Ruth Mokgokong Source Type: research

How prepared are pharmacists to support atrial fibrillation patients in adhering to newly prescribed oral anticoagulants?
Conclusion Results suggest the provision of NMS for NOACs is low. Supporting pharmacists with tailored education and adherence support might foster dissemination.
Source: International Journal of Clinical Pharmacy - September 5, 2017 Category: Drugs & Pharmacology Source Type: research

Fat patients with an irregular heartbeat can REVERSE by losing weight
Around one million people in Britain and up to six times as many in the US suffer from atrial fibrillation, which can cause a stroke and eventually lead to heart failure.
Source: the Mail online | Health - June 20, 2018 Category: Consumer Health News Source Type: news

Variation in anticoagulation for atrial fibrillation between English clinical commissioning groups: an observational study.
CONCLUSION: Anticoagulation for AF has improved substantially in England in association with considerable increases in the eligible population as a result of decreased exception reporting and the use of the CHA2DS2VASc score. There is still substantial room for improvement in most CCGs because, even allowing for exceptions, nine out of 10 CCGs failed to achieve 90% anticoagulation. PMID: 29970397 [PubMed - as supplied by publisher]
Source: The British Journal of General Practice - July 2, 2018 Category: Primary Care Authors: Robson J, Homer K, Ahmed Z, Antoniou S Tags: Br J Gen Pract Source Type: research

Patients ’ Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis
DiscussionAlthough the relative impact of convenience on therapy value is small, patients have different preferences for options within convenience criteria. Besides considerations on safety and effectiveness, physicians should also discuss attributes of convenience with patients, as it can be assumed that alignment to patient preferences in drug prescription and better patient education could result in higher adherence.
Source: American Journal of Cardiovascular Drugs - August 22, 2018 Category: Cardiology Source Type: research

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
ConclusionsAll DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all ‐cause mortality, myocardial infarction, and pulmonary embolism warrant further research.
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Tanja Mueller, Samantha Alvarez ‐Madrazo, Chris Robertson, Olivia Wu, Marion Bennie Tags: ORIGINAL ARTICLE Source Type: research

Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non ‐valvular atrial fibrillation.
ConclusionIn real life D110 and D150 were at least as effective and safer than VKA.
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Patrick Blin, Caroline Dureau ‐Pournin, Yves Cottin, Jacques Bénichou, Patrick Mismetti, Abdelilah Abouelfath, Regis Lassalle, Cécile Droz, Nicholas Moore Tags: ORIGINAL ARTICLE Source Type: research

Substantial Cardiovascular Morbidity in Adults with Lower-Complexity Congenital Heart Disease.
CONCLUSIONS: Individuals with lower-complexity ACHD had higher burden of adverse cardiovascular events relative to the general population that was unaccounted for by conventional cardiovascular risk factors. These findings highlight the need for closer surveillance of patients with mild to moderate ACHD and further investigation into management and mechanisms of cardiovascular risk unique to this growing population of high-risk adults. PMID: 30813762 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2019 Category: Cardiology Authors: Saha P, Potiny P, Rigdon J, Morello M, Tcheandjieu C, Romfh A, Fernandes SM, McElhinney DB, Bernstein D, Lui GK, Shaw GM, Ingelsson E, Priest JR Tags: Circulation Source Type: research

Pages: 1 2 3 4 5 6 7